Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

• Status: Completed
• Trial end date: 2017-07-08
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of Patras
• Treatments: Brimonidine Tartrate; Brinzolamide; Dipivefrin; Lubricant Eye Drops

Criteria

Inclusion Criteria:

• patients scheduled to undergo laser posterior capsulotomy due to posterior capsule opacification (PCO) after uneventful phacoemulsification cataract extraction with implantation of posterior chamber intraocular lenses (IOL/PC).

Exclusion Criteria:

• baseline IOP greater than 21mmHg

• glaucomatous eyes, already under treatment with anti glaucomatic medications

• intraocular surgery except for uncomplicated cataract surgery

• previous photorefractive surgery

• active ocular inflammation or infection

• patients under systemic administration of medications known to affect IOP

• patients with severe respiratory or cardiovascular disease

• pregnant or breast feeding women, and individuals with known hypersensitivity or contraindication for administration of the medications tested

• a measurement of IOP > 30 mmHg at any time point of the study, or an increase from baseline >20 mmHg